Seres Therapeutics, which is developing therapies that replace beneficial bacteria to treat infections, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Formerly known as Seres Health, the biotech is first...read more
The average tech IPO gained 25% on its first day in 2014. This week's MaxPoint Interactive dropped 15%. IPO highlights during the week of March 2, 2015: • 2 IPOs priced in the past week, an adtech and a biotech •...read more
Summit Therapeutics, which is developing novel therapies for muscular dystrophy and bacterial infections, raised $34 million by offering 3.45 million shares at $9.90, below its expected offer price of $11.54. Summit Therapeutics, which already trades on the AIM...read more
Seres of fortunate events: Seres Therapeutics files for a $100 million IPO to fight infections
Seres Therapeutics, which is developing therapies that replace beneficial bacteria to treat infections, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Formerly known as Seres Health, the biotech is first...read more
US IPO Weekly Recap: 2 IPOs price but MaxPoint misses the point
The average tech IPO gained 25% on its first day in 2014. This week's MaxPoint Interactive dropped 15%. IPO highlights during the week of March 2, 2015: • 2 IPOs priced in the past week, an adtech and a biotech •...read more
Summit Therapeutics prices US IPO at $9.90, 14% below its filed price
Summit Therapeutics, which is developing novel therapies for muscular dystrophy and bacterial infections, raised $34 million by offering 3.45 million shares at $9.90, below its expected offer price of $11.54. Summit Therapeutics, which already trades on the AIM...read more
Week ahead: 2 IPOs during the week of March 2, a biotech and an adtech
After a week without any IPOs, two upcoming deals - a biotech and an adtech - are set to kick off what could be a busy March in...read more